

Chlorpheniramine Maleate Market Expansion: Anticipated To Reach USD 751.4 Million By 2032

PORTLAND, OREGON, UNITED STATES, July 16, 2024 /EINPresswire.com/ -- How big is the [chlorpheniramine maleate market](#)?

According to the report, the global chlorpheniramine maleate Market valued at \$468.6 million in 2022 and is estimated to reach \$751.4 million by 2032, exhibiting a CAGR of 4.9% from 2023 to 2032.



Chlorpheniramine Maleate Market Expansion 2024

Increase in the prevalence of allergic disorders such as allergic rhinitis, common cold, watery eyes, urticaria and various others, increase in urbanization and change in lifestyles and surge in technological advancement drive the growth of the global chlorpheniramine maleate market. However, potential side effects of chlorpheniramine maleate and availability of alternative medicines are hampering the chlorpheniramine maleate market growth. On the contrary, the growing level of air pollution in developing countries and surge in geriatric population are expected to offer remunerative opportunities for expansion of the chlorpheniramine maleate market during the forecast period.

The key factors that drive the growth of the chlorpheniramine maleate market share are rise in awareness of allergies among the population, an increase in demand for antihistamines, and a surge in investments in R&D activities by pharmaceutical companies for the development of more effective antihistaminic drugs. For instance, in September 2021, Sun Pharmaceutical Industries announced the launch of a novel formulation in cough management, Chericof 12 (dextromethorphan hydrobromide 30 mg and chlorpheniramine maleate 4 mg), in India. Chericof 12, the first prescription cough syrup in India that gives relief for up to 12 hours, is manufactured using polistirex technology for sustained release of the drug.

Request Sample Copy of the Report- <https://www.alliedmarketresearch.com/request-sample/3975>

Top Key Points:

The tablets segment to maintain its leadership status throughout the forecast period

The allergy segment to maintain its leadership status throughout the forecast period

The hospital pharmacies segment to maintain its lead position during the forecast period

North America to maintain its dominance by 2032

Drivers:

Increase in the prevalence of allergic conditions

Rise in urbanization and changes in lifestyles

Surge in technological advancement

Opportunities:

High growth potential in developing economies

Restraints:

Potential side effects of chlorpheniramine maleate

Availability of alternative medicines

Chlorpheniramine relieves red, itchy, watery eyes; sneezing; itchy nose or throat; and runny nose caused by allergies, hay fever, and the common cold. It helps to control the symptoms of cold or allergies but will not treat the cause of the symptoms or speed recovery. Chlorpheniramine is in a class of medications called antihistamines. It works by blocking the action of histamine, a substance in the body that causes allergic symptoms. It is available in various formulations, including tablets, injections, syrups, and as an ingredient in combination medications for cold and allergy relief. It is also sometimes used as a sleep aid due to its sedative effects.

Based on application, the allergy segment held the highest market share in 2022, accounting for around one third of the global chlorpheniramine maleate market revenue and is estimated to maintain its leadership status throughout the forecast period, owing to the rise in prevalence of allergic conditions and expansion of the pharmaceutical industry across the world that provides chlorpheniramine maleate-based formulations to treat allergic disorders. However, the hay fever (allergic rhinitis) segment is projected to manifest a significant CAGR of 6.4% from 2023 to 2032,

owing to an increase in prevalence of allergic rhinitis, a surge in demand for antihistamines and a rise in geriatric population.

Chlorpheniramine Maleate Market Report Highlights:

By Dosage Form:

Tablets
Syrup
Eye Drops

By Application:

Allergy
Hay Fever (Allergic Rhinitis)
Common Cold
Watery Eyes
Itchy Throat/Skin
Anaphylactic Shock
Urticaria

By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

By Region:

North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, Spain, Rest of Europe)
Asia-Pacific
LAMEA

For Purchase Inquiry- <https://www.alliedmarketresearch.com/purchase-enquiry/3975>

Leading Market Players: -

Alkeem Laboratories Ltd
Bayer AG
GlaxoSmithKline plc
Johnson & Johnson
Merck & Co. Inc.

Novalab Healthcare Pvt. Ltd.
Capellon Pharmaceuticals
Sun Pharmaceutical Industries Limited
Viatris Inc.
Zydus Lifesciences Limited.

About Allied Market Research:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.

David Correa
Allied Market Research
+1 800-792-5285

[email us here](#)

Visit us on social media:

[Facebook](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/727937739>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.